Kim Linton
University of Manchester
141 Papers
462 Citations
Kim Linton is an academic researcher from University of Manchester. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 22, co-authored 97 publications. Previous affiliations of Kim Linton include Manchester Academic Health Science Centre & National Health Service.
Chat about Author
Papers
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Andrés José Maria Ferreri,Kate Cwynarski,Elisa Jacobsen Pulczynski,Maurilio Ponzoni,Martina Deckert,Letterio S. Politi,Valter Torri,Christopher P. Fox,Paul La Rosée,Elisabeth Schorb,Achille Ambrosetti,Alexander Röth,Claire Hemmaway,Angela Ferrari,Kim Linton,Roberta Rudà,Mascha Binder,Tobias Pukrop,Monica Balzarotti,Alberto Fabbri,Peter Johnson,Jette Sønderskov Gørløv,Georg Hess,Jens Panse,Francesco Pisani,Alessandra Tucci,Stephan Stilgenbauer,Bernd Hertenstein,Ulrich Keller,Stefan W. Krause,Alessandro Levis,Hans J. Schmoll,Franco Cavalli,Jürgen Finke,Michele Reni,Emanuele Zucca,Gerald Illerhaus +36 more
TL;DR: The IELSG32 trial provides a high level of evidence supporting the use of MATRix combination as the new standard chemoimmunotherapy for patients aged up to 70 years with newly diagnosed primary CNS lymphoma and as the control group for future randomised trials.
530
Drug-Induced Interstitial Lung Disease: A Systematic Review
Sarah Skeoch,Nicholas D Weatherley,Andrew J. Swift,Alexander Oldroyd,Christopher S. Johns,Conal Hayton,Alessandro Giollo,Jim M. Wild,John C. Waterton,Maya H Buch,Kim Linton,Ian N. Bruce,Colm Leonard,Stephen Bianchi,Nazia Chaudhuri +14 more
TL;DR: Overall high-quality evidence in D IILD is lacking, and the current review will inform larger prospective studies to investigate the diagnosis and management of DIILD.
319
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial
Andrés José Maria Ferreri,Kate Cwynarski,Elisa Jacobsen Pulczynski,Christopher P. Fox,Elisabeth Schorb,Paul La Rosée,Mascha Binder,Alberto Fabbri,Valter Torri,Eleonora Minacapelli,Monica Falautano,Fiorella Ilariucci,Achille Ambrosetti,Alexander Röth,Claire Hemmaway,Peter Johnson,Kim Linton,Tobias Pukrop,Jette Sønderskov Gørløv,Monica Balzarotti,Georg Hess,Ulrich Keller,Stephan Stilgenbauer,Jens Panse,Alessandra Tucci,Lorella Orsucci,Francesco Pisani,Alessandro Levis,Stefan W. Krause,Hans J. Schmoll,Bernd Hertenstein,Mathias J. Rummel,Jeffery Smith,Michael Pfreundschuh,Giuseppina Cabras,Francesco Angrilli,Maurilio Ponzoni,Martina Deckert,Letterio S. Politi,Juergen Finke,Michele Reni,Franco Cavalli,Emanuele Zucca,Gerald Illerhaus +43 more
TL;DR: The results of the second randomisation that addresses the efficacy of myeloablative chemotherapy supported by autologous stem-cell transplantation (ASCT) as an alternative to whole-brain radiotherapy (WBRT) as consolidation after high-dose-methotrexate-based chemoimmunotherapy were reported.
317
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
Martin Dreyling,Franck Morschhauser,Krimo Bouabdallah,Dominique Bron,David Cunningham,Sarit Assouline,Gregor Verhoef,Kim Linton,Catherine Thieblemont,Umberto Vitolo,Florian Hiemeyer,M. Giurescu,J. Garcia-Vargas,Igor Gorbatchevsky,Li Liu,Karl Koechert,Carol Peña,M Neves,Barrett H. Childs,Pier Luigi Zinzani +19 more
TL;DR: Intravenous copanlisib demonstrated promising efficacy and manageable toxicity in heavily pretreated patients with various subtypes of indolent and aggressive malignant lymphoma.
260
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
Martin Hutchings,Rogier Mous,Michael Roost Clausen,Peter Johnson,Kim Linton,Martine E.D. Chamuleau,David John Lewis,Anna Sureda Balari,David Cunningham,Roberto S. Oliveri,Brian Elliott,Dena DeMarco,Ada Azaryan,Christopher Chiu,Tommy Li,Kuo mei Chen,Tahamtan Ahmadi,Pieternella J. Lugtenburg +17 more
TL;DR: In this article, the safety and recommended phase 2 dose of epcoritamab, a novel bispecific antibody that targets CD3 and CD20 and induces T-cell-mediated cytotoxic activity against CD20+ malignant B cells, were established.
251